Functional Assessment of Geriatric Cancer Patients Needed

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 3
Volume 10
Issue 3

NEW YORK-Despite considerable progress in the management and treatment of cancer in the overall population, cancer-related mortality among the elderly increased by 20% between 1970 and 1984. Cancer is often undertreated in the elderly, which affects their prognosis, said Roberto Bernabei, MD, of the Universita Cattolica del Sacro Cuore, Rome.

NEW YORK—Despite considerable progress in the management and treatment of cancer in the overall population, cancer-related mortality among the elderly increased by 20% between 1970 and 1984. Cancer is often undertreated in the elderly, which affects their prognosis, said Roberto Bernabei, MD, of the Universita Cattolica del Sacro Cuore, Rome.

Dr. Bernabei, who spoke at the Fifth International Conference on Geriatric Oncology, believes a new approach is needed to "deal with the ‘peculiarities’ of the elderly cancer patient." At his institution, Dr. Bernabei and his colleagues have developed and use a comprehensive geriatric assessment tool.

The new instrument, Minimum Data Set for Cancer (MDS-CA), documents the patient’s oncologic screening and treatment data, and provides a structured, multidimensional assessment of the patient’s general health, including cognitive and functional parameters, emotional and behavioral patterns, nutritional status, co-morbidities, lifestyle and preventive measures, quality of life, pain status, activity and movement status, continence status, informal support availability, and overall medications. "Such a tool," Dr. Bernabei said, "will provide an assessment that can help us build treatment decisions and monitor the treatment."

They have used this new instrument on 220 consecutive elderly patients referred to the oncologic consultation team after a new diagnosis of cancer. "We wanted to define the functional characteristics of these patients and understand who was treated with chemotherapy/radiotherapy and why," he said. Dr. Bernabei stressed that this approach already has shown "considerable benefits in different settings and for conditions other than cancer."

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content